# Genentech, Inc.: Phase 2 study closed enrollment, 30 enrolled (Hepatocellular Carcinoma)

**Score:** 65/100

| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis |
| NCT ID | NCT06096779 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Hepatocellular Carcinoma |
| Intervention types | drug |
| Target enrollment | 30 |
| Site countries | United States, Puerto Rico |
| Posted | 2023-10-24 |
| Planned start | 2024-07-15 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-08 |
| Last update posted | 2026-10-08 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06096779). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.